Y-Mabs Therapeutics Inc’s recently made public that its Officer Wilms Joris acquired Company’s shares for reported $73450.0 on Aug 26 ’24. In the deal valued at $14.69 per share,5,000 shares were bought.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Ber Gerard sold 722 shares, generating $8,664 in total proceeds. Upon selling the shares at $12.00, the Director now owns 1,608 shares.
Before that, Gad Thomas sold 35,000 shares. Y-Mabs Therapeutics Inc shares valued at $421,050 were divested by the CHIEF BUSINESS OFFICER at a price of $12.03 per share. As a result of the transaction, Gad Thomas now holds 197,681 shares, worth roughly $2.99 million.
Cantor Fitzgerald initiated its Y-Mabs Therapeutics Inc [YMAB] rating to an Overweight in a research note published on August 16, 2024; the price target was $20. A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. Wedbush also remained covering YMAB and has increased its forecast on May 10, 2023 with a “an Outperform” recommendation from previously “Neutral” rating. Guggenheim revised its rating on April 03, 2023. It rated YMAB as “a Neutral” which previously was an “a Buy”.
Price Performance Review of YMAB
On Monday, Y-Mabs Therapeutics Inc [NASDAQ:YMAB] saw its stock jump 10.12% to $15.13. Over the last five days, the stock has gained 21.14%. Y-Mabs Therapeutics Inc shares have risen nearly 121.85% since the year began. Nevertheless, the stocks have risen 164.97% over the past one year. While a 52-week high of $20.90 was reached on 03/01/24, a 52-week low of $4.69 was recorded on 01/03/24. SMA at 50 days reached $12.06, while 200 days put it at $11.88.
Levels Of Support And Resistance For YMAB Stock
The 24-hour chart illustrates a support level at 14.14, which if violated will result in even more drops to 13.15. On the upside, there is a resistance level at 15.70. A further resistance level may holdings at 16.27. The Relative Strength Index (RSI) on the 14-day chart is 69.82, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.72, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 2.18%. Stochastics %K at 89.68% indicates the stock is a selling.
How much short interest is there in Y-Mabs Therapeutics Inc?
A steep rise in short interest was recorded in Y-Mabs Therapeutics Inc stocks on 2024-07-31, growing by 1.07 million shares to a total of 4.66 million shares. Yahoo Finance data shows the prior-month short interest on 2024-06-28 was 3.59 million shares. There was a rise of 23.03%, which implies that there is a positive sentiment for the stock.
